CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,103 enrolled
Drug / intervention
Best-Worst Scaling (Case 2) +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02637622
NCT02637622N/ACompleted

Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes

Johns Hopkins Bloomberg School of Public Health·observational·Posted Dec 22, 2015·Updated Nov 29, 2024

In Brief

An observational study evaluating Best-Worst Scaling (Case 2) and Discrete Choice Experiment for Type II Diabetes. Completed, enrolled 1,103 participants across 1 site.

Detailed Summary

In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification requests. In addition to a detailed description of benefits and risks, CDRH listed "patient tolerance for risk and perspective on benefit" as a factor that CDRH may consider in regulatory reviews. It underlined the need for developing methods to measure patient preference and incorporate it into regulatory decision-making. The purpose of this study is to advance methods for patient and community engagement in patient-centered outcome research (PCOR) and has three objectives. First, demonstrate good practices for patient and community involvement in PCOR projects by applying principles of community-based participatory research (CBPR). Second, address methodological gaps pertaining to the use of stated-preference methods in studying preferences in PCOR. These include identifying the best methods for designing a preference study and strategies for analyzing variation in preferences. The investigators also seek to assess the relevance of stated-preference methods to patients and stakeholders using both qualitative and quantitative methods. Third, demonstrate good practices for applying stated-preference methods by studying the preferences of patients with type II diabetes. While type II diabetes provides an important case study, this research will advance approaches and methods that will be broadly generalizable to other diseases, and to diverse patient and stakeholder groups. Clinical Significance: This project will illustrate and advance methods for assessing the values of patients and stakeholders. It will demonstrate how CBPR methods apply to PCOR studies and the value of stated-preference methods in measuring the preferences of patients and stakeholders and directing health care.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 22, 2015
Enrollment StartJul 1, 2013
Primary CompletionOct 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.5 years ago

Interventions

Best-Worst Scaling (Case 2)other

Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.

Discrete Choice Experimentother

Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.